Search
Now showing items 1-3 of 3
Comprehensive analysis of cancers of unknown primary for the biomarkers of response to immune checkpoint blockade therapy
(
Elsevier Ltd
, 2018 , Article)
Background: Cancer of unknown primary (CUP) accounts for approximately 3% of all malignancies. Avoiding immune destruction is a major cancer characteristic and therapies aimed at immune checkpoint blockade are in use for ...
Potential Novel Therapy Targets in Neuroendocrine Carcinomas of the Breast.
(
Elsevier
, 2018 , Article)
Neuroendocrine carcinoma (NEC) of the breast is a rare, special type of breast cancer, reportedly constituting 2% to 5% of all breast cancers. Although breast NEC does not have a specific targeted therapy, several new ...
Composition of the immune microenvironment differs between carcinomas metastatic to the lungs and primary lung carcinomas.
(
Elsevier
, 2018 , Article)
Lungs are among the most common sites for development of both primary and metastatic carcinomas. Tumor cells expression (TC) of PD-L1 is an important predictor of the of response to immune check-point inhibition in NSCLC, ...